Elacytarabine Failure Leaves Clavis Scrambling For Buyer
This article was originally published in The Pink Sheet Daily
The Phase III failure of Clavis’ AML candidate elacytarabine likely spells the end of the road for the Norwegian company and its lipid vector technology approach to drug development. Clavis is aiming to find a buyer or merger option or considering closing its doors.
You may also be interested in...
The failure of Clavis Pharma's and Clovis Oncology's novel potential pancreatic cancer therapy CP-4126/CO-101 in the pivotal LEAP trial was associated with the surprising failure of a novel personalized medicine approach to treating the devastating disease.
First Humira biosimilar launches raise worries about holes in US health system that may let the brand product continue to dominate. If Humira biosimilars can’t get a strong foothold, reform to biosimilar policy for medicines reimbursed through the pharmacy benefit may be necessary if the US wants to rely on these products to bring down the cost of brand biologics.
Marks appeared to use the variable EUA bar to justify what many viewed as early mistakes by FDA during COVID-19, and to emphasize the importance of physician awareness of the strength of evidence used to authorize a drug.